Delayed Recall – Patient Perspectives, Part II (January 2018)

Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy

Long-term benefit of enzyme-replacement therapy in Pompe disease: A 5-year prospective study

Delayed Recall – Patient Perspectives, Part I (December 2017)

Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study

Multiparametric MRI changes persist beyond recovery in concussed adolescent hockey players

Infliximab for the treatment of central nervous system sarcoidosis: A multi-institutional series

This variant alters protein function, but is it pathogenic?

Delayed Recall – Immunotherapy (November 2017)